Artificial intelligence chatbots could help with the introduction of a twice-yearly shot that can help prevent HIV, experts ...

A new study aims to help healthcare providers more effectively implement Apretude, a medication used for HIV prevention.

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

A larger role for China, perhaps, and the fraught issue of integrating HIV services into services for other diseases.

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Kenya has been picked among nine countries for the trials of the new injectable HIV prevention drug that has been rolled out ...

MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.

The World Health Organization (WHO) is recommending a twice-yearly injection of lenacapavir for prevention of HIV, according ...

Conference on HIV Science officially opened Monday in the Rwandan capital of Kigali, with a strong call to accelerate access to long-acting HIV prevention and treatment innovations amid growing global ...

The temporary suspension of PEPFAR has disrupted preventive treatments, infant testing, and the work of community health ...